(Q51312581)

English

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.

scientific article published on 10 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P D Home

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

P Shamanna

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

M Stewart

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

F Yang

4

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

M Miller

5

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

C Perry

6

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

M C Carr

7

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

publication date

10 December 2014

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

17

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

179-187

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Standards of medical care in diabetes--2010.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

AACE comprehensive diabetes management algorithm 2013.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Standards of medical care in diabetes--2014

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinic

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12414

21 January 2018

Identifiers

10.1111/DOM.12414

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/25406730

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51312581&oldid=1254550353"